Raymond James Initiates Coverage On LENZ Therapeutics with Outperform Rating, Announces Price Target of $37
Portfolio Pulse from Benzinga Newsdesk
Raymond James has initiated coverage on LENZ Therapeutics with an Outperform rating and set a price target of $37.
September 27, 2024 | 5:09 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Raymond James has initiated coverage on LENZ Therapeutics with an Outperform rating and a price target of $37, indicating a positive outlook for the stock.
The initiation of coverage with an Outperform rating by Raymond James suggests a positive sentiment towards LENZ Therapeutics. The price target of $37 indicates potential upside, which is likely to positively impact the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100